Head to Head Review: Psyence Biomedical (PBM) vs. Its Peers

Psyence Biomedical (NASDAQ:PBM) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its peers? We will compare Psyence Biomedical to similar companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.

Institutional & Insider Ownership

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 51.1% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Psyence Biomedical and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Psyence Biomedical Competitors	-1,366.20%	-644.36%	-28.41%

Earnings and Valuation

This table compares Psyence Biomedical and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Psyence Biomedical	N/A	$1.01 million	0.70
Psyence Biomedical Competitors	$959.16 million	-$46.30 million	11.78

Psyence Biomedical’s peers have higher revenue, but lower earnings than Psyence Biomedical. Psyence Biomedical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Psyence Biomedical and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1	0	0	0	1.00
Psyence Biomedical Competitors	5512	12037	37428	1135	2.61

As a group, “MED – BIOMED/GENE” companies have a potential upside of 60.94%. Given Psyence Biomedical’s peers stronger consensus rating and higher possible upside, analysts plainly believe Psyence Biomedical has less favorable growth aspects than its peers.

Risk & Volatility

Psyence Biomedical has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Psyence Biomedical’s peers have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.

Summary

Psyence Biomedical peers beat Psyence Biomedical on 8 of the 13 factors compared.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.